Drug Profile
Research programme: 3-phosphoinositide-dependent kinase-1 inhibitors - Bayer HealthCare Pharmaceuticals
Alternative Names: BX-320; BX-517; BX-795; BX-912; PDK1 inhibitors - Bayer HealthCare PharmaceuticalsLatest Information Update: 23 Mar 2010
Price :
$50
*
At a glance
- Originator Berlex Biosciences
- Class
- Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; TBK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours